Logistics: a game of chess or emotions?
Technological advancements in all its glory, but we must never forget the importance of humanity in customer satisfaction
Watching the Future
Sitting Down With… Peter Marks
Director of the Center for Biologics Evaluation and Research (CBER) at the FDA, USA
Nanoform technology delivers successful results for Herantis CDNF drug candidate
Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that the nanoforming process has been successfully applied to Herantis’ rhCDNF drug candidate.
Nanoform and Boehringer Ingelheim execute master services agreement
Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform’s award-winning CESS® technology can deliver to its drug development projects. The...
Nanoform and Celanese Explore Ways to Enhance Drug Delivery
Together, Nanoform and Celanese will investigate the potential for enabling next-generation drug delivery devices by combining Nanoform’s nanoparticle platform technologies and Celanese’s VitalDose® EVA copolymer delivery technology.
Bio Integrates 2021
The second fully virtual Bio Integrates Conference surpassed expectations, with over 450 delegates attending animated keynote speaker sessions and panel debates, addressing this year’s conference themes of Connection, Projection and Reflection.